What is the management plan for a patient with abnormal left ventricular (LV) strain of -15%?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 1, 2025 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Management of Abnormal Left Ventricular Strain of -15%

A left ventricular (LV) strain of -15% indicates abnormal myocardial function requiring cardioprotective therapy and close monitoring, even if ejection fraction is preserved. This value falls below the normal range (normal being more negative than -18%) and represents subclinical LV dysfunction that requires intervention 1.

Understanding LV Strain and Its Significance

LV global longitudinal strain (GLS) is a sensitive marker of myocardial function that can detect subclinical dysfunction before changes in ejection fraction become apparent. The normal range for LV GLS is:

  • Normal: -18% or lower (more negative)
  • Borderline: -16% to -18%
  • Abnormal: -16% or higher (less negative) 1

A value of -15% is therefore clearly abnormal and indicates impaired longitudinal function of the left ventricle.

Management Approach

1. Initial Evaluation

  • Assess for symptoms of heart failure
  • Determine underlying etiology (cardiomyopathy, valvular disease, cardiotoxic therapy, etc.)
  • Evaluate other cardiac parameters (ejection fraction, chamber dimensions, diastolic function)

2. Cardioprotective Treatment

  • Initiate cardioprotective therapy with ACE inhibitors or ARBs with or without beta-blockers 2
  • This recommendation is particularly strong for patients with abnormal strain but preserved ejection fraction (Stage B heart failure)
  • These medications can prevent further deterioration of LV function

3. Monitoring Protocol

  • Repeat LV ejection fraction and strain measurements every 3 months 2
  • Perform more frequent assessments if cardiac symptoms develop
  • Consider measuring cardiac biomarkers (troponin and BNP/NT-proBNP) based on clinical context and risk of cardiac toxicity 2

4. Special Considerations for Different Clinical Scenarios

For Cancer Patients Receiving Cardiotoxic Therapy:

  • If the patient is receiving cardiotoxic cancer therapy with normal LVEF but abnormal strain:
    • Continue life-saving cancer treatment (treatment should not be altered solely based on changes in LV strain) 2
    • Initiate cardioprotective medications (ACE-I/ARB ± beta-blockers)
    • Consider cardio-oncology consultation 2

For Patients with Suspected Cardiomyopathy:

  • An LV strain of -15% may be suggestive of pathologic LV hypertrophy, particularly in the gray zone of hypertrophic cardiomyopathy (HCM) 3
  • Further imaging with cardiac MRI may be warranted to evaluate for late gadolinium enhancement, which would support a diagnosis of HCM 3

For Patients with Heart Failure:

  • LV GLS ≤10% indicates significantly worse prognosis in heart failure patients 4
  • At -15%, while concerning, the patient has not yet reached this more severe threshold
  • Early intervention with guideline-directed medical therapy is crucial

Prognostic Implications

The prognostic significance of abnormal LV strain is well-established:

  • In heart failure patients, baseline LV GLS is independently associated with long-term outcomes, including worsening heart failure and all-cause mortality 4
  • Improvement in LV GLS over time is associated with better outcomes 5

Common Pitfalls to Avoid

  1. Focusing only on ejection fraction: Normal ejection fraction does not rule out significant myocardial dysfunction. Strain imaging provides incremental prognostic information.

  2. Delaying treatment: Do not wait for symptoms or ejection fraction decline before initiating therapy for abnormal strain.

  3. Inconsistent follow-up: Regular monitoring is essential as LV dysfunction may progress silently.

  4. Ignoring age-related changes: LV strain decreases with age, body weight, central obesity, and relative wall thickness 6, so interpretation should consider these factors.

By implementing early cardioprotective therapy and establishing a regular monitoring protocol, you can potentially prevent progression to more severe LV dysfunction and improve long-term outcomes for patients with abnormal LV strain.

Related Questions

Given the echocardiographic measurements (left‑ventricular stroke volume ~50 mL, low stroke‑volume index, ejection fraction ≈48 %, fractional shortening 27 %, global longitudinal strain –9 %, concentric hypertrophy with relative wall thickness ~0.52, E/A ratio 0.43, E/e′ ≈4.4, aortic valve area 1.0 cm², mean gradient 18 mmHg, peak gradient 33 mmHg, TAPSE 2.1 cm), what is the overall interpretation and what guideline‑directed medical therapy and further work‑up should be recommended?
Given the echocardiogram showing left ventricular ejection fraction 48% in the four‑chamber view (63% in the two‑chamber view), global longitudinal strain –10%, average mitral valve E/e′ 13.8, left atrial volume index 28.6 mL/m², tricuspid annular plane systolic excursion 1.5 cm, and mild aortic stenosis (mean gradient 3 mmHg, peak gradient 6 mmHg, valve area 1.31 cm²), what is the appropriate management?
What does a global longitudinal strain (GLS) of -14% in echocardiography indicate?
What does a global longitudinal strain (GLS) result of -16.2% indicate and how should it be managed?
What does an abnormal left ventricular (LV) strain of -15 indicate and what are its potential causes?
What is the recommended dosing and titration for pyridostigmine (Mestinon) in the treatment of myasthenia gravis?
What is the treatment for a fifth metatarsal diaphysis fracture?
What is the standard rate for normal saline (NS) intravenous (IV) hydration in adults?
What is the recommended approach for bridging warfarin (anticoagulant) therapy after debridement (surgical removal of dead tissue)?
Is Celebrex (celecoxib) safe to use in a patient with Atrial Fibrillation (AFib) and Congestive Heart Failure (CHF)?
What is the recommended approach for a mental health exam in a patient newly diagnosed with lung cancer?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.